TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

In September, the Swiss pharma won back-to-back FDA approvals for subcutaneous versions of its multiple sclerosis drug Ocrevus and cancer immunotherapy Tecentriq. Dubbed Ocrevus Zunovo ...

Ocrevus is a medicine commonly used to treat primary progressive MS, but it can take up to four hours to receive intravenously. A new version called “Ocrevus Zunovo” was recently approved by ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

During the first half of this year, Ocrevus generated 1.04 billion Swiss francs – more than 90% of that was from use in the US. Roche’s MS drug Ocrevus earns blockbuster status a year after ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Ocrevus sales increased 11% to 1.69 billion Swiss francs, while Vabysmo surged 59%. On Wednesday, Roche Holdings AG RHHBY released its third-quarter sales report. Sales increased 9% year over year ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

Roche confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and ...

Moreover, high-efficacy monoclonal antibody therapy -- ocrelizumab (Ocrevus), rituximab (Rituxan), or natalizumab (Tysabri) - ...